Hanlin (02696.HK) announces the completion of Phase 2 clinical study of recombinant anti-PD-1 humanized monoclonal antibody injection (HLX10) in combination with recombinant anti-EGFR humanized monoclonal antibody injection (HLX07) for recurrence or metastatic head and neck squamous cell carcinoma (HNSCC) treatment in China Patients administered in patients.

HLX10, an innovative self-developed biopharmaceuticals intended for solid tumor treatment, is exploring further possibilities for chronic hepatitis B treatment. HLX07 is an innovative, innovative, self-developed novel novel drug targeting EGFR. It is expected to be used for colorectal cancer, nasopharyngeal cancer and other solid tumor indications.

The main objective of the trial is to evaluate the objective remission rate and safety of the 16th week of combined HLX10 and HLX07 therapy for advanced head and neck squamous cell carcinoma. Secondly, it aims to evaluate other efficacy endpoints, immunogenicity, and pharmacokinetic characteristics. Exploratory purposes include identifying biomarkers of treatment response or resistance. (jc/a) ~

ASDAK Financial News

Website: www.aastocks.com